Your browser doesn't support javascript.
loading
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree, Bruce Ac; Selmaj, Krzysztof W; Steinman, Lawrence; Comi, Giancarlo; Bar-Or, Amit; Arnold, Douglas L; Hartung, Hans-Peter; Montalbán, Xavier; Havrdová, Eva K; Sheffield, James K; Minton, Neil; Cheng, Chun-Yen; Silva, Diego; Kappos, Ludwig; Cohen, Jeffrey A.
Afiliação
  • Cree BA; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Selmaj KW; Center for Neurology, Lódz, Poland and Collegium Medicum, Department of Neurology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
  • Steinman L; Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, USA.
  • Comi G; Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy.
  • Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Arnold DL; NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, QC, Canada.
  • Hartung HP; Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany/Brain and Mind Centre, The University of Sydney, Sydney, Australia/Department of Neurology, Medical University of Vienna, Vienna, Austria/Department of Neurology, Palacky University Olomouc, Olomouc, Czech Repub
  • Montalbán X; Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Havrdová EK; Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic.
  • Sheffield JK; Bristol Myers Squibb, Princeton, NJ, USA.
  • Minton N; Bristol Myers Squibb, Princeton, NJ, USA.
  • Cheng CY; Bristol Myers Squibb, Princeton, NJ, USA.
  • Silva D; Bristol Myers Squibb, Princeton, NJ, USA.
  • Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland.
  • Cohen JA; Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
Mult Scler ; 28(12): 1944-1962, 2022 10.
Article em En | MEDLINE | ID: mdl-35765217
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Esclerose Múltipla Recidivante-Remitente / Indanos Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Mult Scler Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Esclerose Múltipla Recidivante-Remitente / Indanos Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Mult Scler Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos